Aktienanalyse zu Reviva Pharmaceuticals Holdings Inc (RVPH)RVPHReviva Pharmaceuticals Holdings Inc

Reviva Pharmaceuticals Holdings, Inc. is a late-stage pharmaceutical company. The Company discovers, develops, and seeks to commercialize therapeutics for diseases representing unmet medical needs. The Company’s pipeline focuses on the central nervous system, inflammatory, and cardiometabolic diseases. Its pipeline includes two drug candidates, brilaroxazine (RP5063) and RP1208. Its lead drug candidate, brilaroxazine, is in clinical development and is to treat multiple neuropsychiatric indications. These include schizophrenia, bipolar disorder (BD), major depressive disorder (MDD), attention-deficit/hyperactivity disorder (ADHD), behavioral and psychotic symptoms of dementia or Alzheimer’s disease (BPSD), and Parkinson’s disease psychosis. Brilaroxazine is also ready for clinical development for two respiratory indications, including pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF). Its RP1208 drug candidate is a triple reuptake inhibitor (TRI). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

RVPH is not a good buy right now for a beginner with a long-term horizon and $50,000-$100,000 to invest. The stock is in a severe downtrend, the company is facing financing and listing risk, analysts have turned more cautious, and the current share price is far below key technical levels. Even though there are a few long-term pipeline positives, the balance of evidence says to avoid buying this stock now.